KRAS and neoplasm: Interestingly, pre-clinical studies on BI-3406 reveal that therapeutic efficacy was not limited to KRAS G12C-mutant models, as it also induced tumor growth inhibition in xenograft models of KRAS G12C (MIA PaCa-2 cells), KRAS G12V (SW620 cells), KRAS G13D (LoVo cells) and KRAS G12S (A549 cells) (132).